These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 26246764)

  • 1. Personalized Diabetes Management: Moving from Algorithmic to Individualized Therapy.
    Subramanian S; Hirsch IB
    Diabetes Spectr; 2014 May; 27(2):87-91. PubMed ID: 26246764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Decision Cycle for Patient-Centered Glycemic Management in Type 2 Diabetes].
    Hsu HC; Lee YJ; Wang RH
    Hu Li Za Zhi; 2019 Dec; 66(6):5-12. PubMed ID: 31802449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Managing type 2 diabetes: going beyond glycemic control.
    Stolar MW; Hoogwerf BJ; Gorshow SM; Boyle PJ; Wales DO
    J Manag Care Pharm; 2008 Jun; 14(5 Suppl B):s2-19. PubMed ID: 18597582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Evidence-Based Medicine Approach to Antihyperglycemic Therapy in Diabetes Mellitus to Overcome Overtreatment.
    Makam AN; Nguyen OK
    Circulation; 2017 Jan; 135(2):180-195. PubMed ID: 28069712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Individualized glycaemic targets and pharmacotherapy in type 2 diabetes.
    Bailey CJ; Aschner P; Del Prato S; LaSalle J; Ji L; Matthaei S;
    Diab Vasc Dis Res; 2013 Sep; 10(5):397-409. PubMed ID: 23711582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating a Glucose-Sensor-Based Tool to Help Clinicians and Adults With Type 1 Diabetes Improve Self-Management Skills.
    Toschi E; Fisher L; Wolpert H; Love M; Dunn T; Hayter G
    J Diabetes Sci Technol; 2018 Nov; 12(6):1143-1151. PubMed ID: 30060682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Personalized Management of Type 2 Diabetes.
    Peter PR; Lupsa BC
    Curr Diab Rep; 2019 Nov; 19(11):115. PubMed ID: 31686226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Shared decision-making in the care of individuals with diabetes.
    Serrano V; Rodriguez-Gutierrez R; Hargraves I; Gionfriddo MR; Tamhane S; Montori VM
    Diabet Med; 2016 Jun; 33(6):742-51. PubMed ID: 27105298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identifying barriers to glycemic control in patients with type 2 diabetes after completion of an accredited education program.
    Gildea CM; Lantaff WM; Olenik NL
    J Am Pharm Assoc (2003); 2017; 57(3S):S211-S216. PubMed ID: 28366601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing combination therapy for type 2 diabetes in adolescents and adults: a case-based approach.
    Elasy TA; Levy P; Davis SN
    J Fam Pract; 2004 Oct; 53(10):815-22. PubMed ID: 15469778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycemic Control in Patients with Diabetic Kidney Disease; Time to Recognize Perils of Iatrogenic Hypoglycemia?Moving away from Intensive Glycemic Control.
    Gupta P; Gupta R; Gupta AK
    J Assoc Physicians India; 2018 Sep; 66(9):70-75. PubMed ID: 31321935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Personalized medicine in diabetes.
    Malandrino N; Smith RJ
    Clin Chem; 2011 Feb; 57(2):231-40. PubMed ID: 21127150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Personalizing Second-Line Type 2 Diabetes Treatment Selection: Combining Network Meta-analysis, Individualized Risk, and Patient Preferences for Unified Decision Support.
    Choi SE; Berkowitz SA; Yudkin JS; Naci H; Basu S
    Med Decis Making; 2019 Apr; 39(3):239-252. PubMed ID: 30767632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diabetes as a case study of chronic disease management with a personalized approach: the role of a structured feedback loop.
    Ceriello A; Barkai L; Christiansen JS; Czupryniak L; Gomis R; Harno K; Kulzer B; Ludvigsson J; Némethyová Z; Owens D; Schnell O; Tankova T; Taskinen MR; Vergès B; Weitgasser R; Wens J
    Diabetes Res Clin Pract; 2012 Oct; 98(1):5-10. PubMed ID: 22917639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Shared Decision-Making in Diabetes Care.
    Tamhane S; Rodriguez-Gutierrez R; Hargraves I; Montori VM
    Curr Diab Rep; 2015 Dec; 15(12):112. PubMed ID: 26458383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advancing therapy in type 2 diabetes mellitus with early, comprehensive progression from oral agents to insulin therapy.
    Vinik A
    Clin Ther; 2007; 29 Spec No():1236-53. PubMed ID: 18046925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycemic targets and medication limitations for type 2 diabetes mellitus in the older adult.
    Thompson AM; Linnebur SA; Vande Griend JP; Saseen JJ
    Consult Pharm; 2014 Feb; 29(2):110-23. PubMed ID: 24513421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of personalized medicine in identifying appropriate candidates for menopausal estrogen therapy.
    Manson JE
    Metabolism; 2013 Jan; 62 Suppl 1():S15-9. PubMed ID: 23018143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The SWEET SPOTS study: a real-world interpretation of the 2012 American Diabetes Association Position Statement regarding individualized A1C targets.
    Bieszk N; Grabner M; Wei W; Bonine NG; Stephenson JJ
    Risk Manag Healthc Policy; 2016; 9():243-251. PubMed ID: 27877071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Path to Personalized Medicine for Type 2 Diabetes Mellitus: Reality and Hope.
    Aghaei Meybodi HR; Hasanzad M; Larijani B
    Acta Med Iran; 2017 Mar; 55(3):166-174. PubMed ID: 28282717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.